Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

doi:10.1378/chest.08-0652

Chest

Volume 133, Issue 6, Supplement, June 2008, Pages 110S-112S

https://doi.org/10.1378/chest.08-0652 Get rights and content

Since publication of the seventh American College of Chest Physicians (ACCP) supplement on antithrombotic and thrombolytic therapy, the results of clinical trials have provided important new information on the management of thromboembolic disorders, and the science of developing recommendations has advanced. In the accompanying supplement, we provide the new and updated recommendations and review several important changes that we have made in our guideline development process.

We again made a conscious effort to increase the participation of female authors and contributors from outside North America, the latter reflecting the widespread use and dissemination of these guidelines internationally. The grading system for the recommendations was adopted in 2006 by the ACCP for all its guidelines, is similar to the increasingly widely used Grades of Recommendation, Assessment, Development, and Evaluation approach, and is described in detail in one of the introductory chapters. While most of the evidence on which recommendations are made remains low quality in fields of pediatric thrombosis, thrombosis in pregnancy, and thrombosis in valvular heart disease, rigorous studies in other fields have resulted in new and strong evidence-based recommendations for many indications.

Section snippets

CONLICT OF INTEREST DISCLOSURES

Dr. Hirshdiscloses that he has received partial support for writing two books, one on Fondaparinux and one on low-molecular-weight heparin.

Dr. Albersdiscloses that he has received grant monies from the National Institutes of Health, Astra, Genentech, Bristol-Myers Squibb, Sanofi, Boehringer Ingelheim, NMT Medical, and Aventis. He is also on the speakers bureau for Boehringer Ingelheim, and advisory committees for Astra, Aventis, Boehringer Ingelheim, NMT Medical, Bristol-Myers Squibb, and

REFERENCES (3)

HJ Schunemann et al.
Methodology for anti- thrombotic and thrombolytic therapy guideline development: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition)
Chest
(2008)

There are more references available in the full text version of this article.

Cited by (294)

Biologics and their delivery systems: Trends in myocardial infarction
2021, Advanced Drug Delivery Reviews
Cardiovascular disease is the leading cause of death around the world, in which myocardial infarction (MI) is a precipitating event. However, current therapies do not adequately address the multiple dysregulated systems following MI. Consequently, recent studies have developed novel biologic delivery systems to more effectively address these maladies. This review utilizes a scientometric summary of the recent literature to identify trends among biologic delivery systems designed to treat MI. Emphasis is placed on sustained or targeted release of biologics (e.g. growth factors, nucleic acids, stem cells, chemokines) from common delivery systems (e.g. microparticles, nanocarriers, injectable hydrogels, implantable patches). We also evaluate biologic delivery system trends in the entire regenerative medicine field to identify emerging approaches that may translate to the treatment of MI. Future developments include immune system targeting through soluble factor or chemokine delivery, and the development of advanced delivery systems that facilitate the synergistic delivery of biologics.
Diagnostic and therapeutic management of venous thromboembolic disease in obese patients
2020, Revue des Maladies Respiratoires
Malgré la forte proportion de patients obèses, ces patients restent sous-étudiés dans le domaine de la maladie veineuse thromboembolique (MVTE). L’obésité est considérée comme un facteur de risque d’embolie pulmonaire et/ou de thrombose veineuse profonde, surtout lorsqu’elle est associée à d’autres facteurs de risque de MVTE. Aucun algorithme diagnostique de MVTE n’est validé dans la population de patients obèses. Pourtant, les examens d’imagerie peuvent être de mauvaise qualité et non interprétables. En prévention de la MVTE, les données concernant les patients obèses reposent essentiellement sur des études de faible niveau de preuve. Hormis dans un contexte de chirurgie bariatrique, une adaptation des posologies d’héparine au poids des patients ne peut être proposée qu’au cas par cas. En traitement curatif, on peut utiliser soit le traitement classique par héparine avec relais par anti-vitamine K (AVK), soit les anticoagulants oruax directs (AOD) avec les restrictions suivantes : selon les recommandations actuelles, les AOD ne doivent pas être prescrits pour des poids excédant 120 kg ou un indice de masse corporelle > à 40 kg/m² ; quant aux héparines, elles doivent être adaptées au poids et surveillées par le dosage de l’activité anti-Xa chez les patients obèses. Les AVK peuvent être utilisés mais nécessitent une surveillance de l’INR. Ainsi, de nouvelles études spécifiquement dédiées aux patients obèses sont actuellement nécessaires dans le domaine de la MVTE pour une meilleure prise en charge diagnostique et thérapeutique.
Despite the high proportion of obese patients this population remains understudied in the field of venous thromboembolic disease (VTE). Obesity is a risk factor for pulmonary embolism and/or deep vein thrombosis, especially when it is associated with other risk factors for VTE. Currently there is no validated diagnostic algorithm for VTE in the population of obese patients. Moreover, imaging examinations can be of poor quality and inconclusive. In the prevention of VTE, data concerning obese patients are mainly based on low-level studies. Apart from the context of bariatric surgery, an adjustment of heparin doses according to the weight of the patient is proposed only on a case-by-case basis. According to the current guidelines, therapeutic fixed dose oral anticoagulants should not be prescribed for patients with weights exceeding 120 kg or a body mass index > 40 kg/m². Heparin doses should be weight adjusted and monitored with anti-Xa activity. Anti vitamin K can be prescribed but require INR monitoring. Therefore, new studies specifically dedicated to obese patients are required in the field of VTE for better diagnostic and therapeutic management.
Progress in the development of antiplatelet agents: Focus on the targeted molecular pathway from bench to clinic
2019, Pharmacology and Therapeutics
Antiplatelet drugs serve as a first-line antithrombotic therapy for the management of acute ischemic events and the prevention of secondary complications in vascular diseases. Numerous antiplatelet therapies have been developed; however, currently available agents are still associated with inadequate efficacy, risk of bleeding, and variability in individual response. Understanding the mechanisms of platelet involvement in thrombosis and the clinical development process of antiplatelet agents is critical for the discovery of novel agents. The functions of platelets in thrombosis are regulated by two major mechanisms: the interaction between surface receptors and their ligands, and the downstream intracellular signaling pathways. Recently, most of the progress made in antiplatelet drug development has been achieved with P2Y receptor antagonists. Additionally, the usage of GP IIb/IIIa receptor antagonists has decreased, because it is associated with a higher risk of bleeding and thrombocytopenia. Agents targeting other platelet surface receptors such as PARs, TP receptor, EP3 receptor, GPIb-IX-V receptor, P-selectin, as well as intracellular signaling factors, such as PI3Kβ, have been evaluated in an attempt to develop the next generation of antiplatelet drugs, reduce or eliminate interpatient variability of drug efficacy and significantly lower the risk of drug-induced bleeding. The aim of this review is to describe the pathways of platelet activation in thrombosis, and summarize the development process of antiplatelet agents, as well as the preclinical and clinical evaluations performed on these agents.
Cost of Healthcare Associated With Deep Vein Thrombosis in Patients Treated With Warfarin in Turkey: 2010-2013 Database Analysis of a Tertiary Care Center
2019, Value in Health Regional Issues
To evaluate the cost of healthcare with respect to the quality of anticoagulation in patients with deep vein thrombosis (DVT) treated with warfarin in daily practice via the database analysis of a tertiary care center in the period 2010 to 2013.
Of 258 307 records in total, 42 582 unique patients with DVT and 32 012 patients with international normalized ratio (INR) measurements were included. Overall, 6720 unique patients with DVT diagnosis and one or more INR measurements were identified, and the records of 4377 out of 6720 unique patients were validated and included in the analysis data set. The cost analysis was based on direct medical costs from the payer’s perspective. Cost items were related to healthcare resource utilization (inpatient and outpatient services) during the study period, which provided a basis for calculation of per-patient, outpatient, inpatient, and total direct medical costs.
Mean outpatient, inpatient, and total hospital admission costs were $578, $2195, and $2785, respectively, for patients with time in the therapeutic range of 70% or more, whereas the same costs were $571, $2163, and $3192, respectively, for patients with time in the therapeutic range of less than 70%.
Our findings for a retrospective cohort of patients with DVT undergoing warfarin therapy reveal that patients spent 70% or more, as opposed to less than 70%, of follow-up time within the therapeutic INR range and that outpatient care, as opposed to inpatient care, was associated with lower healthcare costs. Given the significant contribution that hospital stay makes to the cost burden of DVT, our findings also highlight the association between poor warfarin anticoagulant control and increased hospitalization costs.
Development of Therapeutic Guidelines
2019, Encyclopedia of Pharmacy Practice and Clinical Pharmacy: Volumes 1-3
Therapeutic guidelines are developed mainly to help clinicians and consumers in decision making. Therapeutic guidelines were first developed in the 1970s in Australia. Subsequent use of guidelines has led to improved care quality and patient outcomes. Typically, guidelines are produced by health-care professional associations or governmental health organizations as a guidance to both clinicians and consumers for decision-making process and occasionally to provide evidence about the cost-effectiveness of care leading the way to judicious allocation of resources in health care. A group of experts develops the guidelines based on the best quality clinical research evidence. Prior to publishing, therapeutic guidelines are reviewed and evaluated and are updated regularly. The benefit of developing therapeutic guidelines lies in providing an organized, concise presentation of a large amount of evidence-based data. They may also be harmful if information is lacking or guidelines contain misleading scientific evidence.
Risk factors for anticoagulant-associated gastrointestinal hemorrhage: a systematic review and meta-analysis
2024, Korean Journal of Internal Medicine

View all citing articles on Scopus

: Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).

View full text

Chest

SupplementAntithrombotic and Thrombolytic Therapy, 8th ED: ACCP GuidelinesAntithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Section snippets

CONLICT OF INTEREST DISCLOSURES

Chest

Supplement
Antithrombotic and Thrombolytic Therapy, 8th ED: ACCP Guidelines
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)